Jan S. Rosenbaum, Ph.D

Jan S. Rosenbaum, Ph.D

Company: Kurome Therapeutics

Job title: CEO & CSO


Expert Panel: Finding the Appropriate Niche for Your Kinase Inhibitor in an Evolving Therapeutic & Commercial Landscape 4:30 pm

As the industry becomes increasingly crowded with companies developing kinase inhibitors and alternate therapies, how do you differentiate yourself from the rest? Harnessing the appropriate tools to anticipate where your kinase inhibitor will fit at the point of entering clinical trials Understanding where and how your drug candidate will fit in the evolving market to…Read more

day: Day Two

Revealing IRAK1/4 as an Emerging Target to Override Adaptive Resistance Heme Malignancies 3:00 pm

Reviewing IRAK1/4 signal transduction in cancer cells to inform future development Clarifying the involvement of IRAK1/4 kinase signaling in the development of adaptive resistance Identifying activated forms of IRAK4 in MDS/AML patients to inform effective drug selectionRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.